Emerald Advisers LLC Increases Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Emerald Advisers LLC increased its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 112.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,456,033 shares of the medical technology company’s stock after buying an additional 770,586 shares during the period. Emerald Advisers LLC owned about 1.03% of Alphatec worth $13,366,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ATEC. R Squared Ltd purchased a new position in shares of Alphatec during the fourth quarter valued at $29,000. Nisa Investment Advisors LLC boosted its position in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 4,234 shares in the last quarter. Newton One Investments LLC bought a new stake in Alphatec during the fourth quarter valued at about $50,000. XTX Topco Ltd bought a new stake in Alphatec during the third quarter valued at about $69,000. Finally, AlphaQuest LLC bought a new stake in Alphatec during the fourth quarter valued at about $80,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Insiders Place Their Bets

In other news, COO Scott Lish sold 27,453 shares of the company’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total value of $315,434.97. Following the transaction, the chief operating officer now owns 867,677 shares of the company’s stock, valued at $9,969,608.73. This represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. This trade represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 337,321 shares of company stock valued at $3,828,060. Insiders own 22.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Barclays raised their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. Piper Sandler raised their price objective on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Finally, StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Stock Down 2.6 %

Shares of ATEC stock opened at $9.93 on Friday. The stock has a 50 day moving average of $10.96 and a 200 day moving average of $8.85. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The stock has a market cap of $1.43 billion, a P/E ratio of -7.76 and a beta of 1.39. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $14.54.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The business had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.